Case Study

Supporting first lyophilised mRNA vaccine to trial

Format: PDF file | Document type: Case Study | Promoted Content

This content is provided by Recipharm AB, and any views and opinions expressed do not necessarily reflect those of

Supporting first lyophilised mRNA vaccine to trial

When Arcturus presented its mRNA vaccine candidate to Recipharm, it was at the stage of a frozen product, a ready-to-administer sterile injectable for Phase I & II clinical trials.

The inherent cryogenic logistics and storage costs associated with mRNA vaccines, as well as their intended markets created challenges for Phase III clinical trial and commercialisation.

To mitigate these challenges, Recipharm supported with the technology transfer, qualification and cGMP manufacturing of the lyophilised product to ease the complexities of distribution and extension of vaccine shelf-life.

Related resources from Recipharm AB

Supplier info centre